Contineum Therapeutics, Inc. (CTNM) — 10-Q Filings
All 10-Q filings from Contineum Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Contineum's Q3 Loss Widens Amid R&D Surge, ATM Offering Boosts Cash
— Oct 30, 2025 Risk: high
Contineum Therapeutics, Inc. reported a net loss of $12.8 million for the three months ended September 30, 2025, an increase from $10.3 million for the same per -
Contineum Therapeutics Posts No Revenue, Focuses on R&D
— Aug 5, 2025 Risk: high
Contineum Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net l -
Contineum Therapeutics Q1 2025: Assets $200M, OpEx $6.7M
— May 14, 2025 Risk: medium
Contineum Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $200,000,000 and total liabilities of $19 -
Contineum Therapeutics Q3 2024: Net Loss and Cash Position
— Nov 6, 2024 Risk: medium
Contineum Therapeutics, Inc. reported its financial results for the quarter ended September 30, 2024. The company had total assets of $16,940,594 and total liab -
Contineum Therapeutics Q2 2024: Cash Up, Expenses High
— Aug 14, 2024 Risk: medium
Contineum Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2024. The company had cash and cash equivalents of $16.9 million as o -
Contineum Therapeutics Files 10-Q for Q1 2024
— May 16, 2024 Risk: medium
Contineum Therapeutics, Inc. (CTNM) filed a Quarterly Report (10-Q) with the SEC on May 16, 2024. Contineum Therapeutics reported total assets of $39,630,511 as
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX